Literature DB >> 31310117

A Photochemical Route to Optically Active Hexahydro-4H-furopyranol, a High-Affinity P2 Ligand for HIV-1 Protease Inhibitors.

Arun K Ghosh1, William L Robinson1.   

Abstract

We describe here the syntheses of optically pure (3aS,4S,7aR)-hexahydro-4H-furo[2,3-b]pyran-4-ol and (3aR,4R,7aS)-hexahydro-4H-furo[2,3-b]pyran-4-ol. These stereochemically defined heterocycles are important high-affinity P2 ligands for a variety of highly potent HIV-1 protease inhibitors. The key steps involve an efficient Paternò-Büchi [2 + 2] photocycloaddition, catalytic hydrogenation, acid-catalyzed cyclization to form the racemic ligand alcohol, and an enzymatic resolution with immobilized Amano Lipase PS-30. Optically active ligands (-)-6 and (+)-6 were obtained with high enantiomeric purity. Enantiomer (-)-6 has been converted to potent HIV-1 protease inhibitor 3.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31310117      PMCID: PMC7048240          DOI: 10.1021/acs.joc.9b01361

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  15 in total

1.  Ending the HIV-AIDS Pandemic--Follow the Science.

Authors:  Anthony S Fauci; Hilary D Marston
Journal:  N Engl J Med       Date:  2015-12-01       Impact factor: 91.245

Review 2.  Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance.

Authors:  Arun K Ghosh; Perali Ramu Sridhar; Nagaswamy Kumaragurubaran; Yasuhiro Koh; Irene T Weber; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2006-09       Impact factor: 3.466

Review 3.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.

Authors:  A Wlodawer; J Vondrasek
Journal:  Annu Rev Biophys Biomol Struct       Date:  1998

4.  A simple, continuous fluorometric assay for HIV protease.

Authors:  M V Toth; G R Marshall
Journal:  Int J Pept Protein Res       Date:  1990-12

5.  Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.

Authors:  Arun K Ghosh; Bruno D Chapsal; Abigail Baldridge; Melinda P Steffey; D Eric Walters; Yasuhiro Koh; Masayuki Amano; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2010-12-31       Impact factor: 7.446

6.  Asymmetric One-Pot Synthesis of (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-ol: A Key Component of Current HIV Protease Inhibitors.

Authors:  Adrian Sevenich; Gong-Qing Liu; Anthony J Arduengo; B Frank Gupton; Till Opatz
Journal:  J Org Chem       Date:  2017-01-04       Impact factor: 4.354

Review 7.  Current status and challenges of antiretroviral research and therapy.

Authors:  José A Esté; Tomas Cihlar
Journal:  Antiviral Res       Date:  2009-12-16       Impact factor: 5.970

8.  Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Authors:  Yasuhiro Koh; Hirotomo Nakata; Kenji Maeda; Hiromi Ogata; Geoffrey Bilcer; Thippeswamy Devasamudram; John F Kincaid; Peter Boross; Yuan-Fang Wang; Yunfeng Tie; Patra Volarath; Laquasha Gaddis; Robert W Harrison; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 9.  Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

Authors:  Arun K Ghosh; Zachary L Dawson; Hiroaki Mitsuya
Journal:  Bioorg Med Chem       Date:  2007-09-14       Impact factor: 3.641

10.  C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.

Authors:  Manabu Aoki; Hironori Hayashi; Ravikiran S Yedidi; Cuthbert D Martyr; Yuki Takamatsu; Hiromi Aoki-Ogata; Teruya Nakamura; Hirotomo Nakata; Debananda Das; Yuriko Yamagata; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.